MediciNova ( NASDAQ: MNOV ) said it received a notice of allowance from the Brazilian Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to treat hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
Hypertriglyceridemia is a condition in which triglyceride (fats) levels are elevated, while hypercholesterolemia is a disorder in which the low-density lipoprotein (LDL), also called bad cholesterol, is high. Hyperlipoproteinemia is a disorder caused due to inability to break down lipids or fats in the body, mainly cholesterol and triglyceride.
The company added that the is expected to expire no earlier than July 2034. The allowed claims cover the use of MN-001 or MN-002 for reducing a triglyceride blood level, for reducing a total cholesterol blood level, and for reducing LDL blood level.
MediciNova noted that the allowed claims cover oral administration including liquid and solid dosage forms and a range of doses and dosing frequencies.
"As we already have patents covering similar indications in the U.S., Canada, Europe, Japan, China, and Korea, we believe this additional patent in Brazil could increase the potential value of MN-001," said MediciNova Chief Medical Officer Kazuko Matsuda.
For further details see:
MediciNova to get patent in Brazil for cholesterol lowering therapy